Transscleral Cyclophotocoagulation

The Gold Standard In Glaucoma Treatment

Continuous-Wave Transscleral Cyclophotocoagulation (CW-TSCPC) has been the gold standard in the treatment of severe to end-stage glaucoma for over twenty years. In most cases, this highly effective, durable therapy is a patient’s last option or necessary for immediate and major IOP reduction. CW-TSCPC can be performed using the G-Probe® Delivery Device or the G-Probe Illuminate® Delivery Device.

Established procedure performed for over 20 years
Short learning curve and easy to use 1,2
Well-tolerated 3-6 with limited amount of immediate follow-up
Patient downtime is significantly low
Can be performed in the office or operating room
Low investment for high utility

Surgical Guide

  • Placement: Hold the G-Probe® Delivery Device parallel to the visual axis with the shorter edge of the footplate firmly between the anterior border and the middle of the limbus. Laser delivery is transscleral.
  • Application: Successive applications are spaced one-half the width of the G-Probe footplate apart by aligning a side of the probe over the indented center of the adjacent application.
  • Treatment: Administer 18-21 laser applications per treatment session over 270° (three quadrants, six or seven applications per quadrant), usually omitting the temporal quadrant.
  • Parameters: This array of treatment parameters has been called the “slow coagulation” technique and has proven effective for most eyes. 3 Note that these treatment parameters are suggested by IRIDEX and are based on recommendations by experienced clinicians. Ultimately, it is the physician’s responsibility to determine appropriate treatment parameters for each case. Cautions: Keep the G-Probe tip immersed in a viscous liquid coupling agent (and the eye surface moist) and apply consistent pressure throughout the CWTSCPC treatment. Do not treat over sites of previous trabeculectomies.
Iris Color Power Duration Energy per Application
Dark Brown 1250 mW 4000 ms 5.00 joules
All other 1500 mW 3500 ms 5.25 joules

Patients to Consider

  • The patient is not a surgical candidate for filtration surgery
  • The patient has failed prior filtration surgery and is expected to fail further filtration surgery
  • The patient has a secondary glaucoma in which failure is a likely outcome of filtration surgery (e.g., neovascular, inflammatory, postpenetrating keratoplasty, postscleral buckling).
  • The patient has lost ambulatory level vision and is being treated with cyclophotocoagulation for comfort or to prevent further visual loss.

** External illumination source required.

1 Pucci V, et al. Ophthalmologica 2003. 2 Spencer AF, et al. Br J Ophthalmol 1999. 3 Kosoko O, et al. Ophthalmology 1996. 4 Hawkins TA, et al. Arch Ophthalmol 1993. 5 Bloom PA, et al. Ophthalmology 1997. 6 Brancato R, et al. Eur J Ophthalmol 1995.

Featured Blog Post

SLx Laser Donated to Ivory Coast

SLx Laser Donated to Ivory Coast

At Iridex, we feel passionate about partnering with physicians and organizations that share our mission to fight blindness, improve quality of care, and make a difference in patients’ lives. Recently, through our Iridex Cares program, we partnered with Dr. Andrew Toren (Canada) and Salient Medical Solutions (our distributor in Canada) to bring our laser technology

Read More

Recent News

A menu of glaucoma treatments includes options to fit all scenarios

An article by Michael C. Giovingo, MD, discusses multiple treatment options glaucoma, surgeons have a number of options at their disposal, including MicroPulse Laser Trabeculoplasty (MLT), LicroPulse TLT, and Continuous-Wave TSCPC.

Read More

Transscleral laser therapy device simplifies procedure

MicroPulse Transscleral Laser Therapy (MicroPulse TLT) is a nonincisional procedure that substantially reduces IOP for a broad range of glaucoma patients. Patient-friendly, safe, and effective, MicroPulse TLT is my preferred nonincisional procedure for glaucoma patients before proceeding to surgical interventions to potentially reduce the number of drop therapies or address drop failure.

Read More